A Study to Assess the Effect of Venetoclax on the Pharmacokinetics of Ethinyl Estradiol/Levonorgestrel in Female Subjects With Hematologic Malignancies
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Venetoclax (Primary) ; Ethinylestradiol/levonorgestrel
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Pharmacokinetics
- Sponsors AbbVie
- 31 Jan 2019 Planned End Date changed from 5 May 2020 to 17 Feb 2021.
- 31 Jan 2019 Planned initiation date changed from 15 Dec 2018 to 5 Apr 2019.
- 10 Oct 2018 Planned End Date changed from 30 Mar 2020 to 5 May 2020.